Review Article
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
Table 1
Incidence of SPMs with lenalidomide (Len) maintenance versus placebo in prospective, randomized phase 3 trials.
| | Trial | Reference | | F/ua (mo) | Treatment prior to randomization | Randomized arms | Invasive SPMs (no.) | Solid cancers (no.) | Heme cancers (no.) | Nonmelanoma skin cancers (no.) | Cumulative incidence of invasive cancers (%) | Incidence
(per 100 patient-years) |
| | IFM 2005-002 |
[54] |
614 |
45 | Induction then SCT | Len | 23 | 10 | 13 | 5 | 7.5 | 3.1 | | Placebo | 9 | 4 | 5 | 3 | 2.9 | 1.2 |
| | CALGB 100104 |
[55] |
460 |
34 | Induction then SCT | Len | 18 | 10 | 8 | 4 | 7.8 | N/A | | Placebo | 6 | 5 | 1 | 3 | 2.6 | N/A |
| | | | | | MPR-R | 12 | 5 | 7 | 1 | 7 | 1.4 | | MM-015 | [56, 57] | 459 | 30 | MPR or MP | MPR | 9 | 4 | 5 | 4 | 7 | 2.1 | | | | | | MP | 4 | 3 | 1 | 5 | 3 | 0.7 |
|
|
a
Median followup from the time from randomization.
|
